30
Participants
Start Date
May 12, 2016
Primary Completion Date
April 9, 2019
Study Completion Date
March 8, 2020
Recombinant Human Interleukin-22 IgG2-Fc (F-652)
IV infusion of reconstitution lyophilized F-652.
Systemic Corticosteroids
Prednisone (or equivalent) at the time of the onset of clinical symptoms consistent with GI and/or liver aGVHD, as per the standard of care. Prednisone (or equivalent) will be given at a dose of 2 mg/kg/day and tapered as needed.
MSKCC, New York
MD Anderson Cancer Center, Houston
City of Hope, Duarte
Lead Sponsor
Memorial Sloan Kettering Cancer Center
OTHER
EVIVE Biotechnology
INDUSTRY